GSA Capital Partners LLP Boosts Holdings in Paysign, Inc. (NASDAQ:PAYS)

GSA Capital Partners LLP grew its position in shares of Paysign, Inc. (NASDAQ:PAYS) by 31.2% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 117,028 shares of the company’s stock after purchasing an additional 27,829 shares during the period. GSA Capital Partners LLP owned approximately 0.22% of Paysign worth $429,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in PAYS. SG Americas Securities LLC purchased a new stake in shares of Paysign during the third quarter valued at approximately $43,000. Algert Global LLC purchased a new stake in shares of Paysign during the second quarter valued at approximately $46,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Paysign during the second quarter valued at approximately $66,000. American Century Companies Inc. bought a new stake in shares of Paysign in the second quarter worth $92,000. Finally, BNP Paribas Financial Markets increased its stake in shares of Paysign by 49.7% in the first quarter. BNP Paribas Financial Markets now owns 39,452 shares of the company’s stock worth $144,000 after buying an additional 13,093 shares during the last quarter. Hedge funds and other institutional investors own 25.89% of the company’s stock.

Insider Buying and Selling at Paysign

In other Paysign news, CEO Mark Newcomer sold 25,000 shares of the business’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $3.27, for a total transaction of $81,750.00. Following the completion of the sale, the chief executive officer now owns 9,236,886 shares in the company, valued at $30,204,617.22. The trade was a 0.27 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Matthew Louis Lanford sold 25,360 shares of the business’s stock in a transaction on Friday, November 8th. The shares were sold at an average price of $3.96, for a total transaction of $100,425.60. Following the sale, the insider now owns 109,731 shares of the company’s stock, valued at approximately $434,534.76. The trade was a 18.77 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 301,360 shares of company stock worth $1,112,036 over the last 90 days. Insiders own 23.30% of the company’s stock.

Analyst Ratings Changes

Separately, Barrington Research restated an “outperform” rating and issued a $7.00 price target on shares of Paysign in a research note on Monday, November 4th.

Paysign Trading Up 2.7 %

Shares of NASDAQ:PAYS opened at $3.39 on Thursday. The company has a fifty day simple moving average of $3.87 and a 200 day simple moving average of $4.30. The firm has a market cap of $181.53 million, a PE ratio of 22.60 and a beta of 0.95. Paysign, Inc. has a 12-month low of $2.22 and a 12-month high of $5.59.

Paysign (NASDAQ:PAYS) last issued its quarterly earnings results on Tuesday, November 5th. The company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.02. Paysign had a net margin of 14.28% and a return on equity of 30.64%. The business had revenue of $15.26 million during the quarter, compared to analyst estimates of $14.96 million. During the same quarter in the previous year, the firm earned $0.02 earnings per share. As a group, equities research analysts forecast that Paysign, Inc. will post 0.21 EPS for the current fiscal year.

Paysign Company Profile

Paysign, Inc provides prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing services for businesses, consumers, and government institutions. Its product offerings include solutions for corporate rewards, prepaid gift cards, general purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical payment assistance, and demand deposit accounts accessible with a debit card.